Source - Google-Box
Pfizer’s purported Comirnaty pricing scheme—which could see the company charge between $110 and $130 per vaccine dose on the private market—as “pure and deadly greed.”
To date, more than 650 million COVID-19 vaccine doses have been administered in the U.S., with over 80% of the total population having received at least one shot, explained US officials . But that “public health achievement” is “now at risk” thanks to Pfizer’s greed, they warned.
If Pfizer moves forward with the 400% markup of its BioNTech-partnered shot, as the company “suggested it might” in a recent {billionaire investor event}, it will be putting the lives of “many” uninsured Americans at risk, the lawmakers wrote in a letter addressed to greedy Pfizer CEO, Mr Albert Bourla, Ph.D. “Even worse,” their estimation, is the potential for Pfizer’s price hike to “pave the way” for other vaccine makers like Moderna and Novavax to do the same. Pfizer did not immediately respond to Fierce Pharma's request for comment on the matter.
Pfizer immediately hit social media with its normal playbook : every positive thing they did during pandemic til today, and posting disinformation memes using Politics over facts . Pfizer’s planned price bump on its current medications, beyond its 33 new planned Covid/RSV variant vaccines, medications, and biologicals would come on top of tens of billions of dollars in pandemic revenue the company has generated over the last two years.
Just in 2022’s third quarter—amid an uptake slump for Pfizer and BioNTech’s omicron-tweaked booster shot—Comirnaty brought home $4.4 billion in sales, including $2.9 billion in the U.S. Those results inspired Pfizer to tack another $2 billion onto its vaccine revenue projection for the year, which now stands at $34 billion. Btw , In 2021 they made $37 billion in sales.
Pfizer’s proposed price increases could generate an additional $2.5 billion to $3 billion in yearly revenue, marking yet another massive corporate payday from the ongoing pandemic.
**Pfizer first floated a potential $110 to $130 price tag for Comirnaty during an investor event in October, when the company suggested the price change would occur in 2023—likely in the first quarter—once the U.S. finishes its stockpile of COVID shots and pivots to a commercial model.
In a recent supply contract the
U.S. signed with Pfizer and BioNTech in June of this year, the companies charged 30.48 per dose, which was an increase from a $24 price in July of 2021 and $19.50 per dose in July of 2020. Pfizer proved this week that the pandemic revenue engine still has some fuel left over from
the feds after it revealed a nearly $2 billion deal for another 3.7 million Paxlovid courses for deliver in early 2023.The current administration previously agreed to pay around $10.6 billion, or around $530 per treatment course, for the first 20 million Paxlovid courses ordered. It’s paying around the same amount per course under this latest order.
YESTERDAY NEWS FROM FDA (not just kids 5-11 years old, they are planning to add 6 month old babies through 4 year olds!!) Jan 17, 2023
Breaking news :
Children as young as 6 months old should be eligible for COVID-19 booster shots, the
Food and Drug Administration (FDA), said yesterday. FDA Commissioner Robert Califf, M.D., said in the announcement that “as this virus has changed, and immunity from previous COVID-19 vaccination wanes, the more people that keep up to date on Covid 19 vaccinations, the more benefit for individuals, families and public health by helping prevent severe illnesses, hospitalizations, and deaths.”
(Does the FDA prescribe / recommend drugs to people)??Yesterday’s FDA recommendation comes with caveats about just who and who shouldn’t get the mRNA COVID-19 booster, one being the exclusion of
children who’ve already received three doses of the Pfizer-BioNTech vaccine. Those children will still have protection against the omicron BA.4 and BA.5 subvariants now in circulation.
But this could change, as the FDA in its announcement added that “the data to support giving
an updated bivalent booster dose for these children are expected in January.”Here’s who can receive the booster:Children aged 6 months old through 4 years old who haven’t gotten a three-dose primary series of the Pfizer-BioNTech vaccines. Also, in the same age group, those who haven’t yet gotten the third dose in the series will now be given the bivalent booster as their third dose.
Children aged 6 months old through 5 years old who’ve gotten the monovalent Moderna vaccine will be eligible for the Moderna bivalent booster shot two months after they’ve completed the monovalent dosing.
The booster shots will be
“broadly protective” against COVID-19 because they contain a component that
should ward off the original COVID-19 strain, as well as BA.4 and BA.5, according to the FDA. Some
individuals who receive the bivalent shot could experience side effects like those that affected people who’d gotten the original monovalent vaccines.
In approving the Moderna bivalent vaccine for children 6 months through 5 years old, the FDA analyzed data comparing the immune response among 56 individuals 17 months through 5 years old, finding that “the immune response … was comparable to the immune response to the two-dose primary series in the adult participants.”
The FDA’s recommendation of the Pfizer-BioNTech vaccine for children 6 months through 4 years old “is supported by the FDA’s previous analyses of the effectiveness of primary vaccination with the monovalent Pfizer-BioNTech COVID-19 Vaccine in individuals 16 years of age and older and individuals 6 months through 4 years of age.”
Manufactured for
BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz, Germany
Manufactured by
Pfizer Inc., New York, NY 10017
Revised: 8 December 22
Investor News :
New Term Coined “Tripledemic” Is Covid-19, the Flu, and RSV——————————————————————-
In Europe , an anti body drug Nirsevimab from Sanofi and AstraZeneca gained the European Commission’s marketing authorization to prevent the virus in
{newborns and infants}. This treatment is under review by the FDA for use in the US.
Cases of RSV began appearing earlier than usual during the 2022-2023 RSV season. RSV surged in the US and Europe this alongside the flu and COVID-19 as part of a “Tripledemic” that has been straining hospitals and shortages of fever and pain reducing drugs.
January 17th Moderna announced its mRNA vaccine is 84% effective in its late stage trials in adults over 60. The data is encouraging, and represent the second demonstration of positive phase 3 trial results from our mRNA infectious disease vaccine platform after, Spikevax, our COVID-19 vaccine. We look forward to publishing the full data set and sharing the results at an upcoming infectious disease medical conference,” said Stéphane Bancel, Moderna’s Chief Executive Officer. Currently there are no RSV vaccines and Pfizer’s came in at 66.7% effective the day after the FDA shot down the GlaxoSmithKline (GSK) RSV drug.
Definition RSV :
Respiratory syncytial virus, or RSV, is a (common respiratory
virus that usually causes mild, cold-like symptoms. Most people recover in a week or two). Sounds like the common winter cold...
